Solventum (NYSE:SOLV) Issues FY 2026 Earnings Guidance
by Jessica Moore · The Cerbat GemSolventum (NYSE:SOLV – Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 6.600-6.600 for the period, compared to the consensus EPS estimate of 6.470. The company issued revenue guidance of -.
Wall Street Analyst Weigh In
A number of brokerages have commented on SOLV. KeyCorp reduced their price objective on Solventum from $99.00 to $92.00 and set an “overweight” rating for the company in a research note on Monday, April 27th. Piper Sandler reduced their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Mizuho set a $100.00 price objective on Solventum and gave the company an “outperform” rating in a research note on Tuesday, January 20th. BTIG Research reissued a “buy” rating and issued a $100.00 price objective on shares of Solventum in a research note on Friday, February 27th. Finally, Rothschild & Co Redburn began coverage on Solventum in a research note on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $89.45.
Check Out Our Latest Research Report on Solventum
Solventum Price Performance
Solventum stock traded up $1.65 during midday trading on Tuesday, hitting $69.09. 1,942,446 shares of the company’s stock were exchanged, compared to its average volume of 1,209,391. Solventum has a 52-week low of $62.38 and a 52-week high of $88.20. The stock has a 50-day moving average price of $67.99 and a two-hundred day moving average price of $74.53. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23. The company has a market cap of $11.98 billion, a P/E ratio of 7.79, a PEG ratio of 1.09 and a beta of 0.59.
Solventum (NYSE:SOLV – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities research analysts forecast that Solventum will post 6.5 earnings per share for the current year.
Insider Buying and Selling
In other Solventum news, Director Amy Mcbride Wendell acquired 1,475 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was acquired at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the acquisition, the director owned 5,039 shares in the company, valued at $342,803.17. This represents a 41.39% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.24% of the stock is owned by insiders.
Institutional Trading of Solventum
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Pacer Advisors Inc. boosted its stake in Solventum by 28.2% during the 4th quarter. Pacer Advisors Inc. now owns 17,149 shares of the company’s stock valued at $1,359,000 after purchasing an additional 3,768 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Solventum by 1,482.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 538 shares of the company’s stock valued at $43,000 after purchasing an additional 504 shares during the last quarter. Invesco Ltd. boosted its stake in Solventum by 3.4% during the 4th quarter. Invesco Ltd. now owns 2,930,010 shares of the company’s stock valued at $232,174,000 after purchasing an additional 96,236 shares during the last quarter. Corient Private Wealth LLC boosted its stake in Solventum by 8.3% during the 4th quarter. Corient Private Wealth LLC now owns 44,882 shares of the company’s stock valued at $3,334,000 after purchasing an additional 3,443 shares during the last quarter. Finally, CrossGen Wealth LLC purchased a new stake in Solventum during the 4th quarter valued at $25,000.
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.